| 摘要 |
The present invention relates to compounds of formula (I) that mediate Edg, including Edg-1, 1 processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases that have a significant vascularization or inflammatory component such as in tumor-related diseases. The present invention also relates to compounds that inhibit a5b1, and also that exhibit appropriate selectivity profile(s) against other integrins.
|
| 申请人 |
ASTRAZENECA AB;ASTRAZENECA UK LIMITED;GREWAL, GURMIT;HENNESSY, EDWARD;KAMHI, VICTOR;LI, DANYANG;OZA, VIBHA;SAEH, JAMAL, CARLOS;SU, QIBIN |
发明人 |
GREWAL, GURMIT;HENNESSY, EDWARD;KAMHI, VICTOR;LI, DANYANG;OZA, VIBHA;SAEH, JAMAL, CARLOS;SU, QIBIN |
